Evaluation of Vav3.1 as prognostic marker in endometrial cancer

about

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

Item

http://www.wikidata.org/entity/Q57141071

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 06 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@en

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@nl

type

Item

label

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@en

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@nl

prefLabel

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@en

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@nl

P1476

Evaluation of Vav3.1 as prognostic marker in endometrial cancer

@en

P2093

Alain G Zeimet

http://www.w3.org/2001/XMLSchema#string

Annemarie Wiedemair

http://www.w3.org/2001/XMLSchema#string

Christian Marth

http://www.w3.org/2001/XMLSchema#string

Dominik Wolf

http://www.w3.org/2001/XMLSchema#string

Jiri Hatina

http://www.w3.org/2001/XMLSchema#string

Julia Rössler

http://www.w3.org/2001/XMLSchema#string

P2860

Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins

Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Regulatory and signaling properties of the Vav family

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors

Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis

Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors.

Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.

The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1.

VAV3 mediates resistance to breast cancer endocrine therapy.

Endometrial stem cells in regenerative medicine.

P2888

s00432-018-2725-2

P304

2067-2076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-018-2725-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30083818

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6153599

http://www.w3.org/2001/XMLSchema#string